Wide Ranks

AKRO

Akero Therapeutics, Inc.

32.17

Top Statistics
Market Cap 2 B Forward PE -6.61 Revenue Growth 0.00 %
Current Ratio 17.25 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.81 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 717 M Total Cash Per Share 10.28 Total Debt 36 M
Total Debt To Equity 4.92 Current Ratio 17.25 Book Value Per Share 10.61
All Measures
Short Ratio 602.00 % Message Board Id finmb_571820600 Shares Short Prior Month 4 M
Return On Equity -0.3590 City South San Francisco Uuid 3e1b5569-3af6-3145-abfa-b9e74e9bd948
Previous Close 31.16 First Trade Date Epoch Utc 1 B Book Value 10.61
Beta -0.2600 Total Debt 36 M Volume 376677
Price To Book 3.03 Fifty Two Week Low 15.32 Total Cash Per Share 10.28
Shares Short Previous Month Date 1 B Target Median Price 49.00 Audit Risk 3
Max Age 86400 Recommendation Mean 1.42 Sand P52 Week Change 0.3133
Target Mean Price 48.27 Net Income To Common -237222000 Short Percent Of Float 0.0535
Implied Shares Outstanding 69 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 718470 Average Volume10days 718470 Total Cash 717 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0534 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 31.16 Target Low Price 35.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 30.25 Open 31.14 Free Cashflow -134678496
State CA Dividend Yield 0.00 % Return On Assets -0.2317
Time Zone Short Name EST Board Risk 10 Trailing Eps -3.78
Day Low 30.75 Address1 601 Gateway Boulevard Shares Outstanding 69 M
Compensation Risk 9 Price Hint 2 Target High Price 65.00
Website https://akerotx.com 52 Week Change 0.9217 Average Volume 557050
Forward Eps -4.25 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 1656.80 % Is_sp_500 False Regular Market Day High 32.40
Profit Margins 0.00 % Debt To Equity 4.92 Fifty Two Week High 37.00
Day High 32.40 Shares Short 3 M Regular Market Open 31.14
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0519 Operating Cashflow -211644000 Currency USD
Time Zone Full Name America/New_York Market Cap 2 B Is_nasdaq_100 False
Zip 94080 Quote Type EQUITY Industry Biotechnology
Long Name Akero Therapeutics, Inc. Overall Risk 9 Regular Market Day Low 30.75
Held Percent Institutions 1.05 Current Price 32.17 Address2 Suite 350
Enterprise To Ebitda -5.81 Financial Currency USD Current Ratio 17.25
Industry Disp Biotechnology Number Of Analyst Opinions 11 Country United States
Float Shares 55 M Two Hundred Day Average 25.58 Governance Epoch Date 1 B
Enterprise Value 1 B Forward PE -6.61 Regular Market Volume 376677
Ebitda -269265984 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States.

The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.

The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.

Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.